⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5676 | 0.96 | — | — | |
| Hydrogen Sulfide SCHEMBL27838627 | 0.92 | — | — | |
| Bicarbonate SCHEMBL2178826 | 0.81 | NAPRT (0.48) | — | |
| SCHEMBL4259192 | 0.78 | HSP90AA1 (0.36) | — | |
| Carbamic Acid SCHEMBL285340 | 0.76 | NAPRT (0.50) | — | |
| SCHEMBL4270187 | 0.67 | HDAC8 (0.44) | — | |
| Bromide SCHEMBL6534997 | 0.64 | HDAC8 (0.41) | — | |
| Hydrochloric Acid SCHEMBL7114028 | 0.64 | HDAC8 (0.41) | — | |
| Iodide SCHEMBL6535009 | 0.64 | HDAC8 (0.41) | — | |
| SCHEMBL13217923 | 0.62 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025078686-A1 | COMBINATION THERAPY INVOLVING ANTIBODY-DRUG CONJUGATES AGAINST CLAUDIN18.2 AND PD1/PD-L AXIS INHIBITORS FOR TREATMENT OF CANCER | Sotio Biotech A.S. (CZ) | 2025-04-17 | — | — | WO | claimed |
| US-11788148-B2 | Prognostic and treatment response predictive method | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2023-10-17 | — | — | US | disclosed |
| WO-2021211057-A1 | METHOD OF PREDICTING THE RESPONSIVENESS TO A CANCER THERAPY | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2021-10-21 | — | — | WO | disclosed |
| EP-3695014-B1 | PROGNOSTIC AND TREATMENT RESPONSE PREDICTIVE METHOD | THE INSTITUTE OF CANCER RES ROYAL CANCER HOSPITAL (GB) | 2021-04-14 | — | — | EP | disclosed |
| EP-3695014-A1 | PROGNOSTIC AND TREATMENT RESPONSE PREDICTIVE METHOD | The Institute of Cancer Research: Royal Cancer Hospital (GB) | 2020-08-19 | — | — | EP | disclosed |
| US-20200239968-A1 | PROGNOSTIC AND TREATMENT RESPONSE PREDICTIVE METHOD | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2020-07-30 | — | — | US | disclosed |
| WO-2019074445-A1 | PROGNOSTIC AND TREATMENT RESPONSE PREDICTIVE METHOD | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2019-04-18 | — | — | WO | disclosed |
| US-20160058704-A1 | PLATINUM DRUG FORMULATIONS | CELATOR PHARMACEUTICALS INC. (US) | 2016-03-03 | — | — | US | disclosed |
| EP-2187869-B1 | IMPROVED PLATINUM DRUG FORMULATIONS | CELATOR PHARMACEUTICALS INC (US) | 2015-10-14 | — | — | EP | disclosed |
| US-20120003294-A1 | FIXED RATIO CAMPTOTHECENS/PLATINUM AGENTS | CELATOR PHARMACEUTICALS, INC. (US) | 2012-01-05 | — | — | US | disclosed |
| EP-2187869-A1 | IMPROVED PLATINUM DRUG FORMULATIONS | Celator Pharmaceuticals, Inc. (US) | 2010-05-26 | — | — | EP | disclosed |
| WO-2009097011-A1 | IMPROVED PLATINUM DRUG FORMULATIONS | CELATOR PHARMACEUTICALS, INC. (US) | 2009-08-06 | — | — | WO | disclosed |